Literature DB >> 9157572

HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party.

C R Hay1, W Ollier, L Pepper, A Cumming, S Keeney, A C Goodeve, B T Colvin, F G Hill, F E Preston, I R Peake.   

Abstract

The risk of developing factor VIII inhibitor antibodies in haemophilia A may relate both to factor VIII genotype and genes within the HLA complex known to influence immune response. We investigated a cohort of 176 patients with severe haemophilia A and with either high-level inhibitors (> 10BU/ml) or with no history of an inhibitor, stratified according to the presence or absence of the factor VIII gene intron 22 inversion. HLA DRB1, DQA1 and DQB1 polymorphisms were determined by PCR. HLA frequencies form 137 United Kingdom controls were used for comparison. HLA phenotype frequency differences, expressed as odds ratios with 95% confidence intervals were as follows: HLA-DRB*1501, DQB1*0602 and DQA1*0102 were all increased in frequency in patients with inhibitors, only DQA1*0102 reaching statistical significance (OR 2.7, 1.2-5.9). These alleles form part of an established HLA haplotype. The frequencies of HLA-DRB1*1501, DQB1*0602 and DQA1*0102 were particularly raised in patients with inhibitors and a factor VIII gene intron 22 inversion, although again only DQA1*0102 achieved significance (OR 3.1, 1.0-10.1). The frequency of DRB1*01, DQB1*0501, DQA1*0101 were also increased in inhibitor patients lacking the intron 22 inversion although this failed to achieve statistical significance. This data suggests that HLA class II profile constitutes a weak risk factor for developing inhibitor antibodies to factor VIII. This may be more pronounced in patients with an intron 22 inversion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9157572

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  31 in total

1.  HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

Authors:  R A Ettinger; E A James; W W Kwok; A R Thompson; K P Pratt
Journal:  Haemophilia       Date:  2010-05       Impact factor: 4.287

2.  Mutation analysis of factor VIII in Korean patients with severe hemophilia A.

Authors:  Chur-Woo You; Hee-Sook Son; Hee Jin Kim; Eui-Jeon Woo; Soon-Ae Kim; Haing-Woon Baik
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

Review 3.  Genomics of bleeding disorders.

Authors:  A C Goodeve; A Pavlova; J Oldenburg
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

Review 4.  Violating the theory of single gene-single disorder: inhibitor development in hemophilia.

Authors:  Suad AlFadhli; Rasheeba Nizam
Journal:  Indian J Hematol Blood Transfus       Date:  2014-11-20       Impact factor: 0.900

5.  CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.

Authors:  Katharina N Steinitz; Pauline M van Helden; Brigitte Binder; David C Wraith; Sabine Unterthurner; Corinna Hermann; Maria Schuster; Rafi U Ahmad; Markus Weiller; Christian Lubich; Maurus de la Rosa; Hans Peter Schwarz; Birgit M Reipert
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

Review 6.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 7.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 9.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 10.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.